That difficulty “has reached a point that makes it impossible for the Debtor to sustain its business,” given other challenges facing it, he wrote. To try to deal with that lack of insurance coverage, the company increased the prices of its medications several times since 2015, he wrote. Those price increases, however, exacerbated the problem, he said.